Active Agent Formulations, Methods of Making, and Methods of Use
Active agent compositions comprising active agent particles having an effective average particle size of less than 2000 nm, wherein the compositions comprise a particle sequestrant are disclosed. Compositions having an effective average particle size of less than 2000 nm, wherein the compositions comprise no added surfactants, phospholipids, or combinations thereof, are also disclosed.
1 . An active agent composition comprising
active agent nanoparticles having an effective average particle size of less than 2000 nm, and
a particle sequestrant,
wherein the composition comprises no surfactants or phospholipids, and
wherein the active agent has a water solubility of less than 1 mg/ml.
2 . The active agent composition of claim 1 , wherein the composition is in the form of a suspension.
3 . The active agent composition of claim 2 , wherein the effective average particle size of the nanoparticles in the suspension changes by no more than 35% within 2 weeks of a first particle size measurement.
4 . The active agent composition of claim 1 , wherein the active agent nanoparticles and the particle sequestrant are disposed on an inert core particle to form an active agent granulate.
5 . The active agent composition of claim 1 , wherein the active agent nanoparticles have a D 90 of 1500 nm.
6 . The active agent composition of claim 1 , wherein the active agent nanoparticles have a D 90 of 1000 nm.
7 . The active agent composition of claim 1 , wherein the active agent nanoparticles have a D 90 of 500 nm.
8 . The active agent composition of claim 1 , wherein the active agent comprises sirolimus, thalidomide, or tacrolimus.
9 . The active agent composition of claim 1 , wherein the particle sequestrant comprises a pH-sensitive copolymer having both hydrophobic (meth)acrylate units and acid-soluble (meth)acrylate units.
10 . The active agent composition of claim 1 , wherein the particle sequestrant comprises a butyl methacrylate-(2-dimethylaminoethyl) methacrylate-methyl methacrylate copolymer.
11 . The active agent composition of claim 4 , wherein the inert core particles have an average diameter of 50 to 500 μm.
12 . The active agent composition of claim 4 , wherein the inert core particle comprises a sugar; microcrystalline cellulose; calcium phosphate, lactose; a polymer; and combinations comprising one or more of the foregoing inert core particles.
13 . An active agent suspension comprising
active agent nanoparticles having an effective average particle size of less than 2000 nm, and a particle sequestrant consisting essentially of a butyl methacrylate-(2-dimethylaminoethyl) methacrylate-methyl methacrylate copolymer,
wherein the active agent has a water solubility of less than 1 mg/ml, and
wherein the effective average particle size of the nanoparticles in the suspension changes by no more than 35% within 2 weeks of a first particle size measurement.
14 . The active agent suspension of claim 13 , wherein the active agent nanoparticles have a D 90 of 1500 nm.
15 . The active agent suspension of claim 13 , wherein the active agent nanoparticles have a D 90 of 1000 nm.
16 . The active agent suspension of claim 13 , wherein the active agent nanoparticles have a D 90 of 500 nm.
17 . The active agent suspension of claim 13 , wherein the active agent comprises sirolimus, thalidomide, or tacrolimus.
18 . The active agent suspension of claim 13 , wherein the suspension is disposed on an inert core particle to form an active agent granulate.
19 . An active agent suspension consisting essentially of
active agent nanoparticles having an effective average particle size of less than 2000 nm, and a butyl methacrylate-(2-dimethylaminoethyl) methacrylate-methyl methacrylate copolymer particle sequestrant,
wherein the active agent has a water solubility of less than 1 mg/ml, and
wherein the effective average particle size of the nanoparticles in the suspension changes by no more than 35% within 2 weeks of a first particle size measurement.